Category: Oncotarget

Oncotarget News

Figure 1: (A) Sliced fresh tumor samples were cultured in 96-well plates and viability was measured with PrestoBlue daily for 5 days. X-axis is days, and Y-axis is proportion of viability. (B) Sliced fresh tumor samples were embedded with paraffin, and tissue sections were stained with hematoxylin and eosin (H&E), Masson trichrome, αSMA, CD34 and Ki-67 antibodies.

Real-Time Live Tissue Sensitivity Assay for Pancreatic Adenocarcinoma

September 19, 2023

This approach may allow clinicians to select the most effective therapeutic agents with real time in patients with pancreatic adenocarcinoma.”BUFFALO, NY- September 19, 2023 – A new research paper was... read more

Oncotarget

Systemic Treatment for Brain Metastasis in HER2-Positive Advanced Breast Cancer

September 13, 2023

With these new drugs now available in clinical practice, we expect HER2+/HER2-low BC patients with BMs to live longer and to live better.”BUFFALO, NY- September 13, 2023 – A... read more

Oncotarget

Updates: MET Targeted Therapy for EXON 14 Mutations in Lung Cancer

September 11, 2023

The future looks bright for patients with MET mutations and NSCLC.”BUFFALO, NY- September 11, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on May 26, 2023,... read more

Figure 1: Graphical representation of AIB1Δ4 enabling DCIS invasion and metastasis.

Oncotarget

Subpopulations of AIB1-Expressing Breast Cancer Cells Enable Invasion and Metastasis

September 6, 2023

The data in this paper suggest that even a small subpopulation of AIB1Δ4- expressing cells can enable cell invasion [...]” BUFFALO, NY- September 6, 2023 – A new editorial paper... read more

Figure 5: Correlation between observed AF and expected AF for 401 cancer-associated genes in a tumor tissue sample diluted with the corresponding normal specimen. NeXT Dx™

Oncotarget

Validation of a Comprehensive Genomic Profiling Assay: NeXT Dx™

August 30, 2023

NeXT Dx incorporates a range of features and comprehensive genome variant detection methods that lead to improved disease management and possible enhanced clinical utility.” BUFFALO, NY- August 30, 2023 –... read more

Figure 4: Neoplastic adoption as a pathway of metastasis.

Oncotarget

Adopted Neoplastic Cells and the Consequences of Their Existence

August 29, 2023

I hope that considering and testing the concept of adopted neoplastic cells will prove to be useful in explaining puzzling observations related to neoplasia [...]” BUFFALO, NY- August 29, 2023 –... read more

Oncotarget

Behind the Study: ER Expression Multiclonality in DCIS: Clinical & Future Insights

August 29, 2023

Dr. Mangesh A. Thorat from Guy’s Hospital in London, Queen Mary University of London, and King’s College London, describes a recent editorial he authored that was published by... read more

Oncotarget

A Macrophage is a Macrophage is a Macrophage—in Metastasis

August 23, 2023

We hope that these results will inform future attempts at anti-macrophage therapy and lead to better outcomes for patients in the not-too-distant future.” BUFFALO, NY- August 23, 2023 – A... read more

Oncotarget

Aggressive Luminal Breast Cancer: Are Cis-Spliced Fusion Proteins Pathological?

August 21, 2023

Our findings may provide a useful therapeutic approach for treating breast cancer patients who may suffer from early relapse and intrinsic resistance.” BUFFALO, NY- August 21, 2023 – A new... read more

Figure 1: Glutamine metabolism effect in tumor microenvironment cells.

Oncotarget

Inhibiting Glutamine Metabolism Impacts Tumor Cells or the Microenvironment?

August 16, 2023

These new findings evidence the necessity of more research in Gln metabolism to define the best therapeutic strategies for cancer patients.” BUFFALO, NY- August 16, 2023 – A new editorial... read more